Re: “Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design,Definitions,and Ongoing Challenges for Child and Adolescent Psychopharmacology Research” by Strawn JR and Croarkin PE ( J Child Adolesc Psychopharmacol 2018;28:(5)363)
Restricted accessLetterFirst published online April, 2019
Re: “Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design,Definitions,and Ongoing Challenges for Child and Adolescent Psychopharmacology Research” by Strawn JR and Croarkin PE ( J Child Adolesc Psychopharmacol 2018;28:(5)363)
AtkinsonS, LubaczewskiS, RamakerS, EnglandRD, WajsbrotDB, AbbasR and FindlingRL: Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 28:55–65, 2018.
2.
EmslieGJ, HeiligensteinJH, WagnerKD, HoogSL, ErnestDE, BrownE, NilssonM and JacobsonJG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry, 41:1205–1215, 2002.
3.
StrawnJR, CroarkinPE: Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder: Design, definitions, and ongoing challenges for child and adolescent psychopharmacology research. J Child Adolesc Psychopharmacol, 28:363, 2018.
4.
WeihsKL, MurphyW, AbbasR, ChilesD, EnglandRD, RamakerS and WajsbrotDB: Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 28:36–46, 2018.
